'Eye-opening' innovation as FDA approved eye drops which could replace reading glasses
[Dec 10, 2021: Ryan Curry]
Real-world tests have shown that gait authentication could be a viable means of protecting smartphones. (Credit: iStock Photo)
New eye drops can limit the use for reading glasses.
Vuity has just been approved by the Food and Drug Administration, and local ophthalmologists say it can be a life-changer.
The drops are meant for people dealing with Presbyopia, an age-related eye issue that causes blurry vision.
"We all know the reading glasses are annoying," said Dr. Ella Faktorovich, an ophthalmologist with Pacific Vision Institute. "Within 15 minutes you can see your computer, you can see your phone so you can really improve the range of vision. I think it is huge."
She says the drops target the focusing mechanism in the eye. The drops shrink the pupils and increase focus on the eye.
"There are many kinds of this medicine in trials, but this is the first to be approved," she said. "It is pretty remarkable."
It can help people like Lovester Law, who is currently writing a book. He says he spends hours looking at a screen to write.
"After I read too much or write to long, I just have to close my eyes and relax," he said.
"If we live long enough our eyes are going to age, they are not going to be like they used to be."
People who want the drops will have to consult an eye doctor, because they are only available through a prescription.
Doctors at UCSF say this breakthrough can be a catalyst for future eye treatment.
"The data we have shows that it really really works," said Julie Schallhorn, Associate Professor of ophthalmology at UCSF. "It is an exciting time to be in this field, and an exciting time for our patients."
About the VUITY Clinical Development Program
The FDA approval of VUITY in October 2021 was based on data from two pivotal phase 3 clinical studies, GEMINI 1 and GEMINI 2, which evaluated the efficacy, safety and tolerability of VUITY for the treatment of presbyopia.
A total of 750 participants aged 40 to 55 years old with presbyopia were randomized in the two studies in a one-to-one ratio to either VUITY or placebo.
Participants were instructed to administer one drop of VUITY or placebo once daily in each eye.
Both studies met their primary endpoints with a statistically significant proportion of participants treated with VUITY gaining three lines (the ability to read three additional lines on a reading chart) or more in mesopic (in low light), high contrast, binocular Distance Corrected Near Visual Acuity (DCNVA), without losing more than 1 line (5 letters) of Corrected Distance Visual Acuity (CDVA) at day 30, hour 3, versus placebo.
There were no serious adverse events observed in any participants treated with VUITY in either clinical study. The most common adverse events occurring at a frequency of >5% in participants treated with VUITY were headache and eye redness.
For more science news stories check out our New Innovations section at The Brighter Side of News.
Note: Materials provided above by AbbVie. Content may be edited for style and length.
Like these kind of feel good stories? Get the Brighter Side of News' newsletter.